Open access
Open access
Powered by Google Translator Translator

RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

19 Mar, 2021 | 08:42h | UTC

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial – JAMA

Editorial: Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19 – JAMA


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.